Pharming Group (NASDAQ:PHAR - Get Free Report) had its price objective cut by research analysts at Oppenheimer from $31.00 to $30.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm presently has an "outperform" rating on the stock. Oppenheimer's price objective indicates a potential upside of 239.37% from the stock's current price.
Separately, HC Wainwright restated a "buy" rating and set a $37.00 price objective on shares of Pharming Group in a research report on Thursday.
Read Our Latest Stock Report on Pharming Group
Pharming Group Stock Up 1.6 %
PHAR stock traded up $0.14 during trading on Monday, reaching $8.84. The stock had a trading volume of 2,504 shares, compared to its average volume of 4,875. The company's 50 day moving average is $8.07 and its two-hundred day moving average is $8.51. The company has a market capitalization of $599.62 million, a price-to-earnings ratio of -34.00 and a beta of 0.15. Pharming Group has a one year low of $6.65 and a one year high of $13.20. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41.
Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative return on equity of 7.65% and a negative net margin of 6.09%. The business had revenue of $74.09 million during the quarter, compared to the consensus estimate of $71.95 million. During the same period last year, the business posted $0.02 earnings per share. Equities research analysts forecast that Pharming Group will post -0.15 EPS for the current year.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in Pharming Group (NASDAQ:PHAR - Free Report) by 32.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 23,435 shares of the company's stock after purchasing an additional 5,725 shares during the quarter. Silverberg Bernstein Capital Management LLC's holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. 0.03% of the stock is owned by institutional investors and hedge funds.
Pharming Group Company Profile
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
